Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Change in Accured Expenses (2024 - 2025)

Pelthos Therapeutics has reported Change in Accured Expenses over the past 2 years, most recently at $3.5 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $3.5 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $6.2 million (up 2277.74% YoY), and the annual figure for FY2025 was $6.2 million, up 2277.74%.
  • Change in Accured Expenses for Q4 2025 was $3.5 million at Pelthos Therapeutics, up from -$413476.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for PTHS hit a ceiling of $3.5 million in Q4 2025 and a floor of -$1.6 million in Q2 2024.